SAN DIEGO, Jan. 9, 2026 /PRNewswire/ — Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective first-line (1L) treatment in patients with CLDN18.2 positive metastatic pancreatic ductal adenocarcinoma (mPDAC) Spevatamig’s unique molecular design mitigates hematological toxicity, and improves gastrointestinal (GI) tolerability (nausea and vomiting) […]
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present their Phase 1/2 study results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of […]
SAN DIEGO, Sept. 8, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of spevatamig in combination with chemotherapy for the treatment of biliary tract carcinoma (BTC). Spevatamig is a first-in-class native […]
SAN DIEGO, May 27, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy. Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action […]
SAN DIEGO, May 5, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of peluntamig in combination with Roche’s anti-PD-L1 monoclonal antibody atezolizumab (TECENTRIQ® ). The study is being conducted in a cohort […]
SAN DIEGO, Feb. 19, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of peluntamig (PT217) in combination with chemotherapy. Peluntamig (PT217), a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and […]
This is the second Fast Track Designation granted to PT217 by the agency SAN DIEGO, Dec. 4, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the […]
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that Zev Wainberg, MD, an internationally renowned medical oncologist and professor at David Geffen School of Medicine at UCLA, has joined the Company’s Clinical Advisory Board (CAB). “We are excited to have […]
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of PT886 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The dosing was conducted in a cohort of gastric and […]
SAN DIEGO, Sept. 9, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of PT886 in combination with chemotherapy. Dosing has been completed in two cohorts: one for first-line treatment of pancreatic […]
